Molecular Partners AG American Depositary Shares (MOLN) Stock Price

MOLNStock

$4.38+21.31%52W

Market Cap$164.30M

P/E—

PEG Ratio—

Div yield—

Beta0.38

MOLN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-15.56%

Price vs S&P 500 (4W)8.46%

VGM Score43.79

Book Value / Share (Quarterly)$2.27

P/TBV (Annual)1.70x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-20.13%

Cash Flow / Share (Quarterly)$-2.20

Price vs S&P 500 (YTD)-7.17%

Net Profit Margin (TTM)-866.56%

EPS (TTM)$-2.51

10-Day Avg Trading Volume0.02M

EPS Excl Extra (TTM)$-2.51

Revenue Growth (5Y)-24.59%

EPS (Annual)$-2.06

ROI (Annual)-73.41%

Gross Margin (Annual)99.80%

Net Profit Margin (5Y Avg)-646.31%

Cash / Share (Quarterly)$2.62

ROA (Last FY)-60.38%

EBITD / Share (TTM)$-2.32

ROE (5Y Avg)-31.87%

Operating Margin (TTM)-896.17%

Cash Flow / Share (Annual)$-1.73

P/B Ratio1.92x

P/B Ratio (Quarterly)1.84x

Net Income / Employee (Annual)$-515,833

EV / Revenue (TTM)8.28x

Net Interest Coverage (TTM)-16.57x

ROA (TTM)-70.20%

EV / EBITDA (TTM)0.28x

EPS Incl Extra (Annual)$-2.06

Current Ratio (Annual)8.79x

Quick Ratio (Quarterly)9.21x

3-Month Avg Trading Volume0.02M

52-Week Price Return21.31%

EV / Free Cash Flow (Annual)-0.88x

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.27

P/S Ratio (Annual)26.48x

Asset Turnover (Annual)0.03x

52-Week High$4.94

Operating Margin (5Y Avg)-662.57%

EPS Excl Extra (Annual)$-2.06

CapEx CAGR (5Y)-15.76%

Tangible BV CAGR (5Y)-5.55%

26-Week Price Return-3.42%

Quick Ratio (Annual)8.61x

13-Week Price Return14.61%

Total Debt / Equity (Annual)0.05x

Current Ratio (Quarterly)9.42x

Enterprise Value$88.15M

Revenue / Share Growth (5Y)-31.27%

Asset Turnover (TTM)0.05x

Book Value / Share Growth (5Y)-10.21%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-1087.34%

Cash / Share (Annual)$3.10

3-Month Return Std Dev30.13%

Gross Margin (5Y Avg)98.50%

Net Income / Employee (TTM)$-625,781

ROE (Last FY)-76.74%

Net Interest Coverage (Annual)-12.36x

EPS Basic Excl Extra (Annual)$-2.06

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.05x

EPS Incl Extra (TTM)$-2.51

Receivables Turnover (Annual)0.00x

ROI (TTM)-82.80%

P/S Ratio (TTM)15.41x

Pretax Margin (5Y Avg)-646.32%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$2.68

Price vs S&P 500 (52W)0.82%

Year-to-Date Return4.28%

5-Day Price Return2.02%

EPS Normalized (Annual)$-2.06

ROA (5Y Avg)-23.54%

Net Profit Margin (Annual)-1087.38%

Month-to-Date Return6.01%

Cash Flow / Share (TTM)$-1.13

EBITD / Share (Annual)$-1.87

Operating Margin (Annual)-1231.73%

LT Debt / Equity (Annual)1.55x

ROI (5Y Avg)-30.50%

LT Debt / Equity (Quarterly)1.48x

EPS Basic Excl Extra (TTM)$-2.51

P/TBV (Quarterly)1.84x

P/B Ratio (Annual)1.70x

Pretax Margin (TTM)-866.56%

Book Value / Share (Annual)$2.68

Price vs S&P 500 (13W)11.31%

Beta0.38x

P/FCF (Annual)1.12x

Revenue / Share (TTM)$0.00

ROE (TTM)-85.24%

52-Week Low$3.32

vGradeC

gGradeF

mGradeB

vgmGradeC

MOLN Earnings Surprise History

Q2 25-0.70est. -0.55

Q3 25-0.41est. -0.46

Q4 25-0.45est. -0.37

Q2 26-0.44est. -0.44

MOLN Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.10

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
MOLNMolecular Partners AG American Depositary Shares	C	F	B	$4.38
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Molecular Partners AG American Depositary Shares

Molecular Partners AG is a clinical-stage biopharmaceutical company developing DARPin therapeutics—protein-based drugs targeting serious diseases across three main pipeline areas: oncology, ophthalmology, and immuno-oncology. The company's ophthalmology programs focus on retinal diseases including wet age-related macular degeneration and diabetic macular edema, while its oncology candidates employ novel multi-DARPin compounds with differentiated mechanisms of action. With oncology as its primary therapeutic focus, Molecular Partners advances a pipeline of DARPin-based treatments designed to address significant medical needs in cancer and sight-threatening disorders.